Investor Relations Home

Corporate Profile

NeuroDerm is a clinical-stage pharmaceutical company developing next-generation treatments for central nervous system disorders, through proprietary formulations based on existing drugs that are intended to make a significant difference in patients' lives. NeuroDerm currently has four product candidates in development designed to treat moderate to severe Parkinson’s disease. The company designed its product candidates to overcome major deficiencies of current treatments and achieve enhanced clinical efficacy through continuous, controlled administration, primarily subcutaneously or transdermally.

Title
Download Documentation NeuroDerm Investor Day Slides_April 21 2017

Recent News

More >>
DateTitle 
04/20/17NeuroDerm to Ring the Nasdaq Stock Market Opening Bell and Participate in the Parkinson’s Unity Walk
REHOVOT, Israel, April 20, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that the company’s CEO, Oded S. Lieberman, PhD, will ring The Nasdaq Stock Market Opening Bell in New York on Friday, April 21, 2017. A live stream of the ceremony will be available at http://livestream.com/nasdaq/live from approximately 9:15 a.m. ET until 9:30 a.m. ET. Neuro... 
Printer Friendly Version
04/10/17NeuroDerm to Host Investor Day on April 21, 2017
REHOVOT, Israel, April 10, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced that the Company will host its first Investor Day, taking place in New York on Friday, April 21, 2017. Members of NeuroDerm’s executive team will be joined by key opinion leaders to review the company’s clinical programs for treating patients with moderate and severe Parkinson... 
Printer Friendly Version
03/30/17NeuroDerm Announces Fourth Quarter and Full Year 2016 Financial Results
Files Annual Report on Form 20-F Company to Host Conference Call and Webcast Today at 8:30 a.m. ET REHOVOT, Israel, March 30, 2017 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drug-device combinations for central nervous system (CNS) disorders, today announced financial results for the fourth quarter and 2016 fiscal year ended December 31, 2016, and has filed its annual report on Form 20-F for the fiscal year ended December 31, 2016 wit... 
Printer Friendly Version

Upcoming Events | Past Events

More >>
There are currently no events scheduled.